The occurrence of malignancies in a Hungarian lupus population;Tumorok elofordulása szisztémás lupus erythematosusos betegek körében

Orvosi Hetilap

Volumn 147, Issue 46, 2006, Pages 2229-2233

  Tarr, Tünde ^a,b   Szekanecz, Éva ^b   Zeher, Margit ^a   Szegedi, Gyula ^c   Kiss, Emese ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Onkológiai Tanszék ^*  (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Cancer; Mortality; SLE; Survival

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL EXAMINATION; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITAL DEPARTMENT; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PREVALENCE; SEX DIFFERENCE; SKIN CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CANCER; BLOOD DISEASE; BREAST TUMOR; BRONCHUS TUMOR; GASTROINTESTINAL TUMOR; HEALTH SURVEY; INCIDENCE; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; UTERINE CERVIX TUMOR;

ADULT; AGED; AZATHIOPRINE; BREAST NEOPLASMS; BRONCHIAL NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; GASTROINTESTINAL NEOPLASMS; HEMATOLOGIC NEOPLASMS; HUMANS; HUNGARY; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 34249739050     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bernatsky, S., Bovin, J. F., Joseph, L. és mtsai: An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum., 2005, 52, 1481-1490
2. Bernatsky, S., Ramsey-Goldman, R., Rajan, R. és mtsai: Non-Hodgkin's lymphoma in systemic lupus crythematosus. Ann. Rheum., Dis. 2005, 64, 1507-1509.
3. Bessant, R., Hingorani, A., Patel, L. és mtsai: Risk of coronary heart disease and stroke in a large British cohort of patients with systemic Jupus erythematosus. Rheumatology, 2004, 43, 924-929.
4. Bhattoa, H. P., Bettembuk, P., Balogh, A. és mtsai: Bone mineral density in women with systemic lupus erythematosus. Clin. Rheumatol., 2002, 21, 135-141.
5. Bröjendal, L., Löfstrom, B., Li Yin és mtsa: Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand. J. Rheurnathol., 2003, 31, 66-71.
6. Cibere, J., Sibley, J., Haga, M.: Systemic lupus crythematosus and the risk of malignancy. Lupus, 2001, 10, 394-400.
7. Frostegard, J.: SLE, and atherosclerosis and cardiovascular disease. J. Intern. Med., 2005, 257, 485-589.
8. Hill, C. L., Zhang, Y, Sigureisson, B.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet, 2001, 357, 96-100.
9. Hochberg, M. C.: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1997, 40, 1725.
10. Kadis, C, Kahl, L. és mtsai: Effects of cyclophosphamide on the development of malignancy and on the longterm survival of patients with rheumatoid arthritis: A 20 year follow-up study. Arthritis Rheum., 1995, 38, 1120-1127.
11. Kiss E., Regéczy N., Sonkoly I. és mtsai: Túlélési adatok systemás lupus erythematosusban. MBA, 1998, 51, 237-242.
12. Kiss E., Sonkoly I., Szegedi Gy.: Szisztémás lupus erythematosusban szenvedo betegek követésével szerzett tapasztalataink. Magyar Immunol., 2002, 181, 28-34.
13. Mellemkjaer, L., Andersen, V, Linet, M. és mtsa: Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum., 1997, 40, 761-768.
14. Nieved, O., Bengstsson, A., Jonsen, A.: Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus, 2001, 10, 500-504.
15. Ponyi, A., Constatin, T., Garami, M. és mtsa: Cancer associated myositis: clinical features and prognostic signs. Ann. NY Acad. Sci., 2005, 1051, 64-71.
16. Ramsey-Goldman, R. S. A., Mattai, S. A., Ellen Schilling, E. és mtsai: Increased risk of malignacy in patients with systemic lupus erythematosus. Chicago J. Investig. Med., 1998, 446, 217-222.
17. Rosenthal, A. K., Mclaughlin, J. K., Gridley, G. és mtsa: Incidence of cancer among patients with systemic slerosis. Cancer, J995, 76, 910-914.
18. Roumm, A. P., Medsger, T. A. Jr.: Cancer and systemic sclerosis. An epidemiological study. N. Engl. J. Med., 1996, 326, 363-367.
19. Steibers, A. D., Steinberg. S. C.: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolon only. Arthritis Rheum., 1991, 34, 605-607.
20. Sultan, S. M, Ioannou, Y., Isenberg, D.: Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology, 2000, 39, 1147-1152.
21. Tan, E. M., Cohen, A. S., Fries, J. F és mtsai: The 1982 revised criteria for the classification of systemic lupus erythernatosus. Arthritis Rheum., 1982, 25, 1271-1277.
22. Voulgarelis, M., Pafni, V. G, Isenberg, D. A. és mtsa: Malignant lymphoma in primary Sjörgen's syndrome. A multicentre retrospective, clinical study by the European Concerted Action on Sjörgen's syndrome. Arthritis Rheum., 1999, 42, 1765-1772.
23. Ward, M. M.: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheumatol., 1999, 42, 338-346.